Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early vs Standard ART in HIV (CIPRA HT 001)
NCT00120510Phase 3Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jul 2007
- Primary completion
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lamivudine, zidovudine and efavirenz in human immunodeficiency virus infection (HIV) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Survival at 36 months. Started Jul 2007; status: completed.
02
Drugs
lamivudinezidovudineefavirenz
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00120510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00120510.